MedPath

Risk of Recurrent CeAD After Pregnancy

Recruiting
Conditions
Pregnancy Complications
Cervical Artery Dissection
Registration Number
NCT06258109
Lead Sponsor
University Hospital, Basel, Switzerland
Brief Summary

Primary objective: To determine whether pregnancy increases the risk of recurrent CeAD and delayed stroke in women with prior CeAD based on long-term data.

Methods: Multicentric, observational case-control study based on pooled individual patient data from several stroke centers.

Primary endpoint: Primary composite outcome measure includes the following outcomes: (i) occurrence of recurrent CeAD, (ii) occurrence of ischemic or hemorrhagic stroke, (iii) death.

Detailed Description

Background: Cervical artery dissection (CeAD) is a leading cause of stroke in women of childbearing age. Among the population with an initial CeAD, about 9% show a recurrence event (a range from 0 to 25% has been reported). Recurrence of CeAD can occur for several years after the initial event. CeAD has been shown to occur in association with pregnancy, and the postpartum period, yet it remains unclear whether pregnancy increases the risk of recurrence or delayed stroke. Previous studies on this subject are either based on small sample sizes or lack long-term data.

Objective: The investigators want to determine whether pregnancy increases the risk of recurrent CeAD and delayed stroke in women with prior CeAD based on long-term data.

Furthermore, it will be investigated whether the mode of delivery affects recurrence and if dissections occurred during a particular phase of a woman's reproductive process. The investigators will also investigate if women actively decided against another pregnancy due to the initial CeAD.

Methods: This study will be a multicenter, exploratory case-control study using pooled individual patient data from several stroke centers. The data will be obtained through review of medical records and patient interviews. The study will include all women with any prior CeAD who have had long-term follow-up (at least 6 months, with no upper limit), including information about pregnancy and recurrence of CeAD.

Primary endpoint is a composite outcome measure which consists of (i) occurrence of recurrent CeAD, (ii) occurrence of ischemic or hemorrhagic stroke, (iii) death. Secondary endpoints are the individual components of the primary endpoint and functional outcome assessed by the modified Ranking scale.

Statistical analysis will be used to determine the odds of the primary and secondary endpoints in women who had subsequent pregnancies compared to those who did not.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
1000
Inclusion Criteria
  • female
  • prior symptomatic cervical artery dissection (= index CeAD)
  • at least one long-term follow-up visit (at least 6 months after the initial event)
  • with information available on outcome events:
  • recurrent dissection
  • ischemic stroke
  • hemorrhagic stroke
  • functional outcome assessed by mRS score
  • with data on pregnancy after the initial event
  • at least 18 years old at the initial event
Exclusion Criteria
  • Male patients
  • Age <18 years
  • No long-term follow-up available or long-term follow-up < 6 months after initial event
  • No data on pregnancy after initial event available

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Number of participants with composite outcome measure - recurrent CeAD, ischemic stroke, hemorrhagic stroke and/or deathFrom date of first CeAD until date of latest follow-up assessed up to 35 years

The composite outcome measure includes the following outcome measures during the follow-up: (i) occurence of recurrent cervical artery dissection (CeAD), (ii) occurrence of any ischemic stroke, (iii) occurrence of any hemorrhagic stroke, (iv) death.

Secondary Outcome Measures
NameTimeMethod
Number of participants with recurrent cervical artery dissectionFrom date of first CeAD until date of latest follow-up assessed up to 35 years

assessed by medical history or clinical suspicion with confirmation by cerebrovascular imaging (MRI, MRI angiography, CT, CT angiography, digital subtraction angiography and/or ultrasound)

Number of participants with new ischemic strokeFrom date of first CeAD until date of latest follow-up assessed up to 35 years

assessed by medical history or clinical suspicion with confirmation by cerebrovascular imaging (MRI and/or CT)

Number of participants with new hemorrhagic strokeFrom date of first CeAD until date of latest follow-up assessed up to 35 years

Intracerebral hemorrhage or subarachnoid hemorrhage assessed by medical history or clinical suspicion with confirmation by cerebrovascular imaging (MRI and/or CT)

Number of participants with deathFrom date of first CeAD until date of latest follow-up assessed up to 35 years
Functional outcome as assessed by modified Rankin Scale (mRS)At date of latest, individual follow-up assessed up to 35 years after first CeAD

The scale runs from 0-6, running from perfect health without symptoms to death.

0 - No symptoms.

1. - No significant disability. Able to carry out all usual activities, despite some symptoms.

2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.

3. - Moderate disability. Requires some help, but able to walk unassisted.

4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.

5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.

6. - Dead.

Trial Locations

Locations (12)

Charité Universitätsmedizin, Centrum für Schlaganfallforschung

🇩🇪

Berlin, Germany

Hadassah-Hebrew University Medical Center

🇮🇱

Jerusalem, Israel

Stroke Unit Sanatorio Allende

🇦🇷

Córdoba, Argentina

University of Utah

🇺🇸

Salt Lake City, Utah, United States

Neurology Clinic, University of Brescia

🇮🇹

Brescia, Italy

Neurologische Klinik und Poliklinik, LMU Klinikum Campus Großhadern

🇩🇪

Munich, Germany

University of Virginia

🇺🇸

Charlottesville, Virginia, United States

University Hospital Basel, Stroke Center

🇨🇭

Basel, Switzerland

University Hospital Zurich, Stroke Center

🇨🇭

Zurich, Switzerland

Department of Neurology, Medical University of Innsbruck

🇦🇹

Innsbruck, Tirol, Austria

Helsinki University Central Hospital

🇫🇮

Helsinki, Finland

Stroke Clinic, National Institute of Neurology and Neurosurgery Manuel Velasco Suárez

🇲🇽

Mexico City, Mexico

© Copyright 2025. All Rights Reserved by MedPath